Perioperative pembrolizumab may shift treatment paradigm in resectable HNSCC
24 Jun 2025
byAudrey Abella
In the first interim analysis of the phase III KEYNOTE-689 trial, pembrolizumab improves event-free survival (EFS) and major pathological response (mPR) rate, independent of CPS*, when added to standard-of-care (SoC) treatment for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC).
